Effect of recombinant human Growth Hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients

Claudia Giavoli, Rossella Libé, Sabrina Corbetta, Emanuele Ferrante, Andrea Lania, Maura Arosio, Anna Spada, Paolo Beck-Peccoz

Research output: Contribution to journalArticle


The aim of the study was to evaluate the hypothalamus-pituitary-adrenal (HPA) axis in patients (nine males, three females; mean age ± SEM 51 ± 2 yr) with adult-onset GH deficiency (GHD) due to surgically treated pituitary tumors with preserved HPA function and without evidence of tumor recurrence before and during recombinant human (rh) GH replacement therapy (duration 31 ± 6 months). HPA function was assessed by urinary free cortisol and morning serum cortisol levels as well as cortisol responses to 1 μg ACTH test (n = 7 patients) or insulin tolerance test (n = 5 patients) before and during rhGH therapy, the cut-off for the diagnosis of hypoadrenalism being a cortisol peak less than 18 μg/dl (

Original languageEnglish
Pages (from-to)5397-5401
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Issue number11
Publication statusPublished - Nov 2004


ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this